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Introduction:  Eosinophilic  and  noneosinophilic  Nasal  polyps  (NPs)  are  different  subtypes  of  NPs
and require  different  treatment  methods.
Objectives:  To  compare  the  histologic  characteristics,  mRNA  and  protein  expression  between
Nasal Polyps  with  and  without  eosinophilia.
Methods:  NPs  tissues  were  obtained  from  eighty-six  NPs  patients  during  surgery.  Eosinophilic
and noneosinophilic  NPs  were  distinguished  according  to  immunochemical  results  of  the  speci-
men. The  histological,  mRNA  and  protein  expression  features  were  compared  between  the  two
groups.
Results: In  eosinophilic  NPs,  we  observed  a  signiﬁcantly  higher  GATA-3,  IL-5,  IL-4,  IL-13  mRNA
and protein  expression.  In  noneosinophilic  NPs,  IL-17,  IL-23  and  RORc  mRNA  and  protein  expres-
sion were  increased.  Immunohistochemistry  tests  showed,  more  mast  cells  and  less  neutrophils
in eosinophilic  NPs  compared  with  noneosinophilic  NPs.  Eosinophilic  NPs  patient  presented  more
severe symptom  scores  when  compared  to  noneosinophilic  NPs.
Conclusion:  We  demonstrate  for  the  ﬁrst  time  that  Th2  is  the  predominant  reaction  in
eosinophilic  NPs  while  Th17  is  the  predominant  reaction  in  noneosinophilic  NPs.  Our  study  may
provide new  treatment  strategy  for  NPs.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published





Diferenc¸as  nas  características  de  pólipos  nasais  com  e  sem  eosinoﬁlia
Resumo
Introduc¸ão:  Pólipos  nasais  (PNs)  eosinofílicos  e  não  eosinofílicos  são  diferentes  subtipos  de  PNs
e requerem  diferentes  métodos  de  tratamento. Please cite this article as: Sun C, Ouyang H, Luo R. Distinct characteristics of nasal polyps with and without eosinophilia. Braz J
Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.01.012
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Objetivos:  Comparar  as  características  histológicas  e  a  expressão  de  mRNAs  e  proteínas  entre
PNs com  e  sem  eosinoﬁlia.
Método:  Amostras  de  PNs  foram  obtidos  de  86  pacientes  durante  a  cirurgia.  PNs  eosinofíli-
cos e  não  eosinofílicos  foram  diferenciados  segundo  os  resultados  imunoistoquímicos  de  cada
amostra.  As  características  histológicas  e  de  expressão  de  mRNAs  e  de  proteínas  foram  com-
paradas entre  os  dois  grupos.
Resultados:  Em  PNs  eosinofílicos,  observamos  uma  expressão  signiﬁcativamente  maior  dos
mRNAs e  proteínas  GATA-3,  IL-5,  IL-4  e  IL-13.  Nos  PNs  não  eosinofílicos,  aumentou  a  expressão
dos mRNAs  e  proteínas  IL-17,  IL-23  e  RORc.  Nos  testes  imunoistoquímicos,  observamos  maior
número de  mastócitos  e  menor  número  de  neutróﬁlos  nos  PNs  eosinofílicos,  em  comparac¸ão
com PNs  não  eosinofílicos.  Os  pacientes  com  PNs  eosinofílicos  obtiveram  escores  de  sintomas
mais graves  vs.  PNs  não  eosinofílicos.
Conclusão:  Demonstramos,  pela  primeira  vez,  uma  reac¸ão  Th2  predominante  em  PNs  eosinofíli-
cos e  uma  reac¸ão  Th17  predominante  em  PNs  não  eosinofílicos.  Nosso  estudo  pode  proporcionar
novas estratégias  terapêuticas  para  a  rinossinusite  crônica.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado



































































hronic  rhinosinusitis  (CRS)  is  characterized  by  persistent
nﬂammation  of  nasal  and  paranasal  mucosa,  and  is  divided
nto  two  types  according  to  the  absence  or  presence  of  nasal
olyps  (NPs):  CRS  without  NPs  and  CRS  with  NPs  (CRSwNP).1
istological  features  of  NP  include  inﬂammation  of  Th2  cells
ccompanied  by  inﬁltration  with  eosinophils,  thickening  of
asement  membrane,  and  hyperplasia  of  the  epithelium.2--5
n  Western  populations,  eosinophil  inﬁltration  is  found  in
ost  NPs  and  considered  as  a  major  pathological  marker
f  NPs.6,7 However,  more  and  more  studies  on  Chinese
Ps  showed  that  many  NPs  patients  in  China  presented
s  non-eosinophilic  inﬂammation.8 For  example,  several
tudies  have  shown  that  a  considerable  proportion  of
hinese  NPs  were  neutrophil  dominate,  but  the  detailed
ifference  between  eosinophilic  and  non-eosinophilic  NPs
s  still  unknown.9
Similar  studies  on  asthma  have  demonstrated  that
osinophilic  asthma  is  pharmacologically  responsive  to  glu-
ocorticoid,  but  non-eosinophilic  asthma  may  be  resistant
o  glucocorticoid.10,11 In  a  recent  study  on  the  response  of
Ps  patients  to  oral  corticosteroid  therapy  conducted  by
en,  they  found  eosinophilic  NPs  patients  were  more  sen-
itive  to  corticosteroid  compared  with  non-eosinophilic  NP
atients.12 Besides,  eosinophilic  NPs  had  a  higher  tendency
f  recurrence  after  surgery.  All  these  studies  demonstrated
hat  eosinophilic  and  non-eosinophilic  NPs  may  be  different
ubtypes  of  NPs  and  needed  different  treatment  methods.
This  study  aimed  to  investigate  the  expression  of  key
ranscription  factors  and  cytokines  for  Th1/Th2/Th17  cells
etween  eosinophilic  and  non-eosinophilic  NPs  and  provide
ew  information  on  CRSwNP.
ethodsatients
ighty-six  patients  with  NPs  were  enrolled  consecutively  in





xamination.  According  to  previous  methods,13 eosinophilic
nd  non-eosinophilic  NPs  were  categorized  based  on
mmunochemical  results  by  the  presence  of  either  <5  or
5  eosinophils/high  powered  ﬁelds  (HPF),  respectively.  The
aseline  data  were  collected  and  Lund-Kennedy  and  Lund-
ackey  score  were  obtained  to  evaluate  the  severity  of  NPs.
one  of  the  subjects  used  oral  or  nasal  corticosteroids  during
our  weeks  before  surgery.  Details  of  all  subjects  are  sum-
arized  in  Table  1. This  study  was  approved  by  the  local
thics  committee  (No.  20130106)  and  informed  consent  was
btained.
Every  specimen  was  cut  into  two  portions.  One  portion
as  stored  at  −80 ◦C  for  mRNA  and  protein  analysis.  The
ther  portion  was  used  for  IHC  staining.
ymptom  scores
t  the  clinical  visit,  the  patients  gave  an  overall  assessment
f  their  rhinitis  symptoms.  The  symptoms  of  nasal  blockage,
asal  itching,  sneezing,  and  rhinorrhea  were  rated  on  a  4-
oint  scale,  where  0  =  no  symptoms,  1  =  mild,  2  = moderate,
nd  3  =  severe.  Total  symptom  scores  ranged  from  0  to  12
nd  represented  the  sum  of  the  scores  for  nasal  blockage,
asal  itching,  sneezing,  and  rhinorrhea.
mmunohistochemical  staining
or  immunohistochemistry,  the  sections  underwent  dewax-
ng,  dehydration,  and  then  were  placed  in  0.3%  H2O2 for  20
inutes  at  room  temperature  to  reduce  nonspeciﬁc  back-
round  staining.  After  antigen  retrieval  by  10  mM  citrate
uffer  for  15  minutes,  antihuman  monoclonal  antibodies  for
BP  (eosinophils,  1:100,  Santa  Cruz),  anti-HNE  (neutrophils,
:200,  Dako)  and  anti-tryptase  (mast  cells,  1:100,  Santa
ruz)  were  incubated  overnight  at  4 ◦C  for  immunohisto-
hemical  staining,  respectively.  The  sections  were  washed
ith  PBS  and  incubated  with  secondary  antibody  (Gene  Tech
-  Shanghai,  China)  at  room  temperature  for  one  hour  on  the
ext  day.
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Table  1  Demographic  and  clinical  characteristics  of  eosinophilic  and  non-eosinophilic  NP  patients.
Eosinophilic  NP  Non-eosinophilic  NP  p-value
Sex  (male/female) 22/24  21/19  0.834
Age, years  41.3  39.4  0.235
Duration of  symptoms,  years  7.5  4.1  0.046
Absolute blood  eosinophil  count,  109/L  0.28  0.11  0.013
Proportion of  eosinophils  (%)  2.6  7.8  0.003
Blood IgE  level,  kU/L  112  19  0.001
Patients with  allergy  (%)  65  22  0.002
Lund-Kennedy  score  16.5  10.4  0.012
Lund-Mackey  score 17.8  9.8  0.005
Time of  surgery 2.3  1.1  0.042
Table  2  Primers  used  for  quantitative  PCR  analysis  of
transcriptional  factors  and  cytokine  gene  expression.
Primer  Sequence




























After  washing,  DAB  (Gene  Tech,  Shanghai,  China)  stain-
ing  was  performed  under  microscope  and  the  sections  were
counterstained  with  Mayer’s  hematoxylin  (Dako)  for  40  s,
dehydrated  with  series  ethanol,  cleared  with  xylene  (three
times),  and  mounted  with  neutral  balsam  (Dako).  Control
for  nonspeciﬁc  staining  was  routinely  performed  with  PBS
instead  of  primary  antibodies,  and  all  proved  negative.
The  sections  were  visualized  with  an  Olympus  CX40
Microscope  (Olympus  Europa,  GmbH  --  Germany)  and  the
number  of  positive  cells  was  counted  under  high-power  ﬁelds
(400×).  Ten  ﬁelds  were  counted  in  each  specimen  and  the
median  was  calculated  for  each  antibody.
Real-time  polymerase  chain  reaction  (PCR)  analysis
Real-time  PCR  were  performed  as  previously  described.
Total  mRNA  was  extracted  from  SIP  or  mucosa  tissues
using  TRIzol  reagent  (Life  Technologies--Carlsbad,  CA,
United  States)  according  to  the  manufacturer’s  instruc-
tions.  Reverse  Transcription  (RT)  was  performed,  and
cDNA  was  synthesized  from  2  g  of  total  RNA  using  an
oligo  (dT)  18  primer  and  M-MLV  reverse  transcriptase
(Takara--Syuzou,  Shiga,  Japan).  The  mRNA  expression  was
determined  using  an  ABI  PRISM  7300  Detection  System
(Applied  Biosystems--Foster  City,  CA,  United  States)  and
SYBR  Premix  TaqTM (Takara).  The  sequences  of  the  primers
are  listed  in  Table  2.  PRISM  samples  contained  1×  SYBR
Green  Master  Mix,  1.5  L  of  5  M  primers,  and  25  ng  of  syn-
thesized  cDNA  in  a  25  L  volume.  Reactions  were  heated  to
95 ◦C  for  10  min,  followed  by  40  cycles  of  denaturation  at
95 ◦C  for  10  s,  and  annealing  extension  at  60 ◦C  for  60  s.  All
PCR  reactions  were  performed  in  duplicate.  Melting  curve
analysis  was  used  to  control  for  ampliﬁcation  speciﬁcity.  The
mean  value  of  the  replicates  for  each  sample  was  calculated
and  expressed  as  a  cycle  threshold  (Ct)  value.  The  relative
expression  of  each  target  gene  was  determined  as  the  differ-
ence  (Ct)  between  the  Ct  value  of  the  target  gene  and  the
Ct  value  of  -actin.  Fold  changes  in  the  target  gene  mRNA
were  determined  as  2−Ct.Enzyme-linked  immunosorbent  assay  (ELISA)
Freshly  obtained  tissue  specimen  was  weighed,  and  pro-




3dded  per  100  mg  of  tissue.  The  tissue  was  then  homog-
nized  using  homogenizer  (Kinematica  --  Switzerland)  for
 min  on  ice.  After  homogenization,  the  suspension  was  cen-
rifuged  at  4000  rpm  for  20  min  at  4 ◦C,  and  the  supernatants
ere  stored  at  −80 ◦C  until  analyzed.
Enzyme-linked  immunosorbent  assay  (ELISA)  kits  were
sed  for  measuring  tissue  levels  of  IL-5,  IL-4,  IL-13,
L-17,  IL-23,  IL-8,  and  MPO  (R&D  systems  --  Minneapo-
is,  MN,  United  States)  according  to  the  manufacturer’s
rotocols.  Each  sample  was  tested  in  duplicate.  The
etection  limits  of  the  assays  were  as  follows:  IL-5,
.9  pg/mL,  IL-4,  31.2  pg/mL,  IL-13,  62.5  pg/mL,  IL-17,






































ll  data  were  expressed  as  mean  ±  SD.  Statistical  signif-
cance  between  two  groups  was  determined  using  the
ann--Whitney  U  test.  Signiﬁcant  difference  was  considered
hen  p  <  0.05.
esults
ubjects
ased  on  the  histological  criterion,  46  NP  patients  (53.5%)
ere  classiﬁed  into  the  eosinophilic  subgroup  and  40
P  patients  (46.5%)  were  classiﬁed  into  non-eosinophilic
ubgroup.  The  demographic  and  clinical  characteristics
f  patients  are  displayed  in  Table  1.  Compared  with
on-eosinophilic  NP  patients,  eosinophilic  NP  patients
emonstrated  a  longer  duration  of  symptoms,  higher  blood
bsolute  eosinophil  count,  higher  blood  IgE  level,  higher  per-




































































































igure  1  Comparison  of  mRNA  expression  between  eosinophilic  a
olyps; ENP,  eosinophilic  nasal  polyps. PRESS
Sun  C  et  al.
igher  Lund-Kennedy  and  Lund-Mackey  score,  more  inci-
ence  of  surgery,  and  higher  symptom  scores.  In  term  of
ge  and  sex,  there  was  no  signiﬁcant  difference  between
osinophilic  and  non-eosinophilic  NP  patients.
omparison  of  histology  between  eosinophilic  and
on-eosinophilic  NPs
t  was  found  that  the  number  of  total  inﬂammatory  cells
n  eosinophilic  NPs  increased  signiﬁcantly  compared  with
on-eosinophilic  NPs  (data  not  shown).  Regarding  cell  types,
osinophilic  NPs  have  increased  mast  cells  except  for
osinophils,  whereas  the  non-eosinophilic  NP  presented
ore  neutrophil  inﬁltration  (Table  3).  The  results  also
howed  that  85%  of  eosinophilic  NPs  had  more  than  six
ast  cells  per  HPF,  while  all  non-eosinophilic  NPs  had  lesshan  three  mast  cells  per  HPF.  Meanwhile,  non-eosinophilic
Ps  presented  as  severe  neutrophil  inﬁltration.  90%  of  non-
osinophilic  NPs  had  more  than  ﬁve  mast  cells  per  HPF,  while









































































nd  non-eosinophilic  nasal  polyps.  NENP,  non-eosinophilic  nasal
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Table  3  Median  score  and  95%  reference  range
(mean  ±  SEM)  of  cell  counts  in  eosinophilic  and  non-
eosinophilic  NP  patients  (per  high-powered  ﬁeld).
Eosinophilic  NP  Non-eosinophilic  NP  p-Value
Eosinophil  9.3  (8.8  ±  2.1)  2.8  (2.6  ±  0.3)  0.02
Neutrophil  1.5  (1.7  ±  0.5) 6.3  (5.4  ±  1.5)  0.04
























eosinophils  contribute  to  the  development  of  NPs.  However,NP, nasal polyps.
When  the  relationship  between  the  number  of  eosinophils
and  other  cells  was  also  analyzed,  it  was  found  that  the  num-
ber  of  eosinophils  correlated  positively  with  the  number  of
mast  cells  (r  =  0.68;  p  <  0.001)  and  total  inﬂammatory  cells
(r  =  0.46;  p  <  0.05),  but  no  relationship  was  found  between
eosinophils  and  neutrophils.
Comparison  of  mRNA  expression  between
eosinophilic  and  non-eosinophilic  NPs
In  eosinophilic  NPs,  signiﬁcantly  higher  Th2  (GATA-3,  IL-5,  IL-
4,  IL-13)  transcription  factor  and  cytokines  expression  were
observed,  while  in  non-eosinophilic  NPs,  Th17  (RORC,  IL-
17A,  and  IL-23)  transcription  factor  and  cytokines  showed
increased  expression  (Fig.  1).  For  Th1  (T-bet  and  IFN-)
transcription  factor  and  cytokines,  no  difference  was  found




































































Figure  2  Comparison  of  protein  expression  between  eosinophilic  
ENP, eosinophilic  nasal  polyps. PRESS
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omparison  of  protein  expression  between
osinophilic  and  non-eosinophilic  NPs
imilar  with  the  mRNA  expression,  Th2  cytokines  (IL-5  and
L-13)  protein  were  signiﬁcantly  higher  in  eosinophilic  NPs
nd  Th17  cytokines  (IL-17A  and  IL-23)  protein  were  signiﬁ-
antly  higher  in  non-eosinophilic  NPs  (Fig.  2).  However,  IL-4
rotein  expression  was  undetectable  in  both  groups  (data
ot  shown).  As  for  Th1  cytokines  (IL-12  and  IFN-) expres-
ion,  no  difference  was  found  between  two  groups  (data  not
hown).  It  was  also  found  that  expression  of  markers  of  neu-
rophil  (IL-8,  MPO)  in  non-eosinophilic  NPs  was  higher  than
hat  of  eosinophilic  NPs.  The  relationship  between  cytokine
xpression  was  also  analyzed;  it  was  found  that  IL-17A  was
ositively  related  to  both  IL-8  and  MPO  expression  (r  =  0.53,
 <  0.01;  r  =  0.57,  p  <  0.05).
iscussion
n  Western  populations,  NPs  are  considered  to  be  orches-
rated  by  Th2  cells,  and  tissue  eosinophilia  is  a  very
mportant  feature.14--16 The  inﬁltration  and  activation
f  eosinophils  in  nasal  mucosa  can  promote  secre-
ion  of  speciﬁc  granule  proteins,  synthesis,  and  release
f  lipid  mediators,  inﬂammatory  cytokines,  chemokines,
nd  growth  factors.  Through  these  chemical  mediators,everal  studies  have  demonstrated  that  less  than  50%  of  NP
atients  in  China  or  other  Asian  countries  had  eosinophilic





























































































































































eterogeneous  and  can  be  broadly  divided  into  two  sub-
ypes:  eosinophilic  and  non-eosinophilic  NPs.  Eosinophilic
Ps  can  be  well-controlled  by  corticosteroid  therapy,  while
on-eosinophilic  NPs  are  responsive  to  a  combination  of
ndoscopic  sinus  surgery  and  macrolide  therapy.19--21
In  the  present  study,  the  eosinophilic  NP  group  demon-
trated  a  higher  prevalence  of  allergy  and  IgE  levels.
ince  blood  eosinophil  count  is  signiﬁcantly  correlated
ith  eosinophil  inﬁltration  in  the  nasal  polyps,  the  blood
osinophil  count  could  be  a  good  marker  for  the  eosinophilic
nﬂammation  of  NPs.  All  these  data  suggested  that  the
ccurrence  of  eosinophilic  NPs  was  closed  related  to  allergy.
owever,  the  role  of  allergy  in  the  pathogenesis  of  NPs  is
till  controversial.  A  few  studies  have  questioned  the  role  of
llergy  in  the  pathogenesis  of  NPs.  Caplin  et  al.  evaluated
000  atopic  patients  and  found  that  only  0.5%  of  patients
ad  NPs.  Other  reports  were  also  unable  to  support  either  a
igher  incidence  of  atopy  in  patients  with  NPs  or  a  pattern  of
llergic  inﬂammation  in  the  pathogenesis  of  NPs.22--24 Thus,
he  present  study  requires  further  validation  by  studies  with
arger  sample  size.  It  was  also  found  that  eosinophil  inﬁl-
ration  was  directly  correlated  with  disease  severity,  since
oth  total  and  each  item’s  score  were  higher  in  eosinophilic
Ps.  Besides,  higher  Lund-Kennedy  and  Lund-Mackey  scores
n  eosinophilic  NPs  were  also  found.  Taken  together,  these
esults  suggest  that  eosinophilic  NPs  predict  long  disease
uration  and  poor  prognosis.
In  the  histological  test,  it  was  found  that  more  severe
nﬂammatory  reaction  in  eosinophilic  NPs  presented  as
ore  mast  cells  and  eosinophils  inﬁltration,  and  more  neu-
rophil  inﬁltration  in  non-eosinophilic  NPs.  Mast  cells  are
he  major  effector  cell  of  IgE-mediated  allergic  reactions  by
eleasing  histamine  and  other  chemicals  involved  in  allergic
nﬂammation;  their  inﬁltration  into  eosinophilic  NPs  sug-
ested  that  a  T-cell-mediated  immune  response  may  play
n  important  role  in  eosinophilic  NPs.  Consistent  with  these
esults,  the  data  showed  that  the  number  of  eosinophils
as  positively  correlated  with  the  number  of  mast  cells
nd  total  inﬂammatory  cells.  Neutrophil  inﬁltration  is  often
elieved  to  be  related  with  bacterial  infection,  but  the
resent  results  demonstrated  that  neutrophil  inﬁltration
as  also  involved  in  chronic  inﬂammation.  Nagakura  sug-
ested  that  high-molecular-weight  neutrophil  chemotactic
ctivity  was  related  to  nasal  hypersensitivity.  In  addition,
lastase  released  by  neutrophils  after  degranulation  may
lso  play  an  important  role  in  tissue  damage.25,26
Previous  studies  had  conﬁrmed  the  role  of  Th  cell  in
he  pathogenesis  of  CRS,  thus,  the  present  study  compared
he  expression  of  mRNA  and  protein  expression  between
wo  groups.  The  results  revealed  Th2  predominant  reaction
n  eosinophilic  NP  and  Th17  predominant  reaction  in  non-
osinophilic  NP.  However,  Th1  (T-bet  and  IFN-) transcription
actors  and  cytokines  expression  were  found  between  the
wo  groups.  GATA-3  is  necessary  for  commitment  toward
h2  cells  and  controls  the  expression  of  IL-5.27--30 The
pregulation  of  GATA-3  in  eosinophilic  NP  was  reﬂected
y  the  subsequent  increase  of  the  IL-5  mRNA  and  pro-
ein.  As  a  marker  for  Th17  cells,  the  transcription  factor
ORC  was  analyzed  and  signiﬁcantly  higher  expression  was
ound  in  non-eosinophilic  NPs.31,32 Similarly,  Th17  cytokines
IL-17A  and  IL-23)  protein  were  signiﬁcantly  higher  in  non-
osinophilic  NPs.  Consistent  with  these  results,  previous
1 PRESS
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tudied  have  shown  that  the  IL-17-IL-23  axis  plays  important
oles  in  the  pathogenesis  of  NPs.  As  expected,  markers  of
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